Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
07:16pm, Thursday, 10'th Jul 2025
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
01:01pm, Wednesday, 09'th Jul 2025
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Tuesday, 08'th Jul 2025
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know
07:16pm, Thursday, 12'th Jun 2025
Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
01:11pm, Thursday, 05'th Jun 2025
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
10:00am, Monday, 02'nd Jun 2025
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif. , June 2, 202
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
01:06pm, Thursday, 29'th May 2025
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio Stock Slips Despite New China Distribution Deal With Haorui
11:51am, Friday, 23'rd May 2025
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
PACB Stock May Rise Following the Deal With Chulalongkorn University
02:05pm, Monday, 12'th May 2025
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated
10:56am, Monday, 12'th May 2025
MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independ
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates
01:01pm, Friday, 09'th May 2025
Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say
10:00pm, Thursday, 08'th May 2025
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metri
Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript
07:08pm, Thursday, 08'th May 2025
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christ
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
06:31pm, Thursday, 08'th May 2025
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.
PacBio Announces First Quarter 2025 Financial Results
04:15pm, Thursday, 08'th May 2025
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025.
